PT  - JOURNAL ARTICLE
AU  - Remes-Troche, Jose María
AU  - Ramos-De-la-Medina, Antonio
AU  - Manríquez-Reyes, Marisol
AU  - Martínez-Pérez Maldonado, Laura
AU  - Solis-Gonzalez, María Antonieta
AU  - Hernández Flores, Karina Guadalupe
AU  - Cid, Héctor Vivanco
TI  - Prevalence of SARS-CoV-2 IgG antibodies in a population from Veracruz (Southeastern Mexico)
AID  - 10.1101/2020.10.19.20215558
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.19.20215558
4099  - http://medrxiv.org/content/early/2020/10/21/2020.10.19.20215558.short
4100  - http://medrxiv.org/content/early/2020/10/21/2020.10.19.20215558.full
AB  - Introduction/Aim Recent studies have shown that seroprevalence is quite variable depending on the country, the population and the time of the pandemic in which the serological tests are performed. Here, we investigated the prevalence of IgG antibodies against SARS-CoV-2 in a population living in Veracruz City, México.Methods From of June 1 to July 31, 2020, the consecutive adult patients (age ≥18 years) that attended 2 ambulatory diagnostic private practice centers for testing were included. Samples were run on the Abbott Architect instrument using the commercial Abbott SARS-CoV-2 IgG assay. The main outcome was seroprevalence. Demographics, previous infection to SARS-CoV-2 (according to a previous positive polymerase-chain reaction nasopharyngeal swab), self-suspicious of virus of infection (according to have in the previous 4 weeks either fever, headache, respiratory symptoms but not a confirmatory PCR) or no having symptoms were also evaluated.Results A total of 2174 subjects were tested, included 53.6% women (mean age 41.8±15.17 years, range 18-98 years). One thousand and forty-one (52.5%) subjects were asymptomatic, 722 (33.2%) had suspicious of infection and 311 (14.3%) had previous infection. Overall, 642 of 2174 (29.5% [95% CI 27.59%-31.47%]) of our population were seropositive. Seropositivity among groups was 21.3% in asymptomatic, 23.4% in self-suspicious patients and 73.9% in previous infection patients.Conclusions We found one of the highest seroprevalences reported for SARS-CoV-2 worldwide in asymptomatic subjects (21.3%) as well in subjects with self-suspicious of COVID-19 (23.4%). The number of infected subjects in our population is not encouraging and it should be interpreted with caution.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Hospital Espanol institutional review board approved this research.(HE-2020-005)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIf requested